Our Perspectives

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

Transposon Announces Final Results from a Phase 2 Study of its LINE-1 Reverse Transcriptase Inhibitor TPN-101 for the Treatment of Progressive Supranuclear Palsy and Interim Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia

Mineralys Therapeutics Announces $120 Million Private Placement Financing

Renalys Pharma Is Launched To Bring New Innovative Medicines To Patients In Japan and Other Countries In Asia

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

Aculys Pharma delivers positive Phase 3 clinical study interim analysis result of a diazepam nasal spray: an antiepileptic drug for the treatment of epileptic seizures

Catalys Pacific Strengthens Company Creation Team with New Partner

Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea

Arialys Therapeutics Launches to Lead the Development of New Precision Medicines for Autoimmune Neuropsychiatric Diseases

Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension

Catalys Pacific Adds Experienced Pharmaceutical Executive as Advisor

Catalys Pacific Adds Experienced Pharmaceutical and Biotech Executive as Advisor

Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering

Aculys Pharma Initiates a Phase 3 Trial of pitolisant Treating Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea Syndrome

Pathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 Studies

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

Aculys Pharma initiates a phase 3 clinical study of a diazepam nasal spray: an antiepileptic drug for the treatment of epileptic seizures

Aculys Pharma initiates a phase 3 clinical study of the histamine H3 receptor antagonist/inverse agonist pitolisant in patients with narcolepsy in Japan

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

HilleVax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

HilleVax Announces Initiation of Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants

Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis

Aculys Pharma Closes US$24 Million Series B Financing

Catalys Pacific Launches Kirilys Therapeutics as a Multi-asset Precision Oncology Company

Catalys Pacific Calls for Economical Disengagement from Russian Industry

Pathalys Pharma, Inc. Launches with Mission to Address High Priority Needs in Chronic Kidney Disease

Catalys Pacific Adds Experienced Pharmaceutical Executive to Life Sciences Team

Aculys Pharma Initiated a Phase 1 Clinical Trial of pitolisant, a histamine H3 receptor antagonist / inverse agonist, in Japan

Aculys Pharma signed an exclusive licensing agreement with Neurelis, Inc. for the development and commercialization of VALTOCO®

Aculys Pharma Closes US$60 Million Series A Financing Led by SoftBank Vision Fund 2

Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial

Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection

HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate

Remembering Catalys Pacific Industry Advisor Tadataka ‘Tachi’ Yamada, MD (1945-2021)

Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints

Mineralys Therapeutics Closes $40 Million Series A Funding

Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial

Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial

Catalys Pacific Strengthens Company Creation Team with New Operating Partner

Domain Associates and Catalys Pacific Launch Exalys Therapeutics to Develop Portfolio of Next-Generation EP4 Antagonists

Catalys Pacific Strengthens Company Creation Team with New Industry Advisor

Phathom Pharmaceuticals Announces Pricing of Initial Public Offering and Begin trading on the Nasdaq

Japanese Foreign Minister’s Commendations for FY 2019 to Dr. Slingsby, Founder & Managing Partner of Catalys Pacific

Catalys Pacific Launches in Japan to Advance Early-Stage Life Sciences Innovation by Creating and Investing in Global Companies

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals